Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer

Chambers, Setsuko K.

doi:10.3390/cancers14205020

Cited by 6 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 35 In recent years, treatment guidelines for EC have been updated to include targeted treatments such as immune checkpoint inhibitors. 36 , 37 …”

Section: Discussionmentioning

confidence: 99%

“…35 In recent years, treatment guidelines for EC have been updated to include targeted treatments such as immune checkpoint inhibitors. 36,37 Homologous sequencing has led to the identification of 3 GRHL genes in the human genome to date. 14 Recent years have seen a surge in the publication of multiple studies on GRHL and cancer, and these findings provide compelling evidence that GRHL is strongly associated with cancer.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Exploration of the Correlation Between GRHL1 Expression and Tumor Microenvironment in Endometrial Cancer and Immunotherapy

Guo,

Bai,

Cui

et al. 2024

PGPM

View full text Add to dashboard Cite

Introduction GRHL1 belongs to the family of Grainyhead-like (GRHL). Previous studies have shown that dysregulation of growth and survival pathways is associated with the GRHL family of gene cancers. Immunotherapy with checkpoint inhibitors has changed the treatment paradigm for many tumors, including endometrial cancer (EC). However, the effect of GRHL1 on immunotherapy in EC and its relationship with immune cell infiltration are poorly understood. Methods Differential expression of GRHL1 between EC and normal EC tissues was analyzed by searching the TCGA database, and the results were verified utilizing immunohistochemistry analyses. Next, the relationship between GRHL1 , CD8+ T cells and tumor microenvironment (TME) was also investigated, and the effect of GRHL1 expression on immunotherapy in EC was evaluated. Results According to the findings, EC tissues had elevated expression levels of GRHL1 relative to normal tissues. Patients with EC who expressed GRHL1 at high levels experienced worse overall survival (OS) and Progression-free survival (PFS) than those whose expression was lower. In addition, GRHL1 expression was negatively correlated with CD8+ T cells, and patients with high GRHL1 expression were less effective in receiving immunotherapy. Conclusion The expression of GRHL1 was high in EC patients, and high expression of GRHL1 inhibits the proliferation of CD8+ T cells in the tumor microenvironment of EC and affect the efficacy of immunotherapy.

show abstract

“… 35 In recent years, treatment guidelines for EC have been updated to include targeted treatments such as immune checkpoint inhibitors. 36 , 37 …”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Exploration of the Correlation Between GRHL1 Expression and Tumor Microenvironment in Endometrial Cancer and Immunotherapy

Guo,

Bai,

Cui

et al. 2024

PGPM

View full text Add to dashboard Cite

show abstract

“…In recent years, improved molecular characterization has furthered the development and testing of targeted therapies [27,28]. Recent studies have demonstrated improved outcomes in patients with advanced and recurrent endometrial cancer treated with immunotherapy in combination with traditional cytotoxic chemotherapy [29,30].…”

Section: Discussionmentioning

confidence: 99%

Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience

Mercado,

Badiner,

Wang

et al. 2023

Cancers

View full text Add to dashboard Cite

We aimed to determine the incidence, treatment regimen, and treatment outcomes (including progression-free survival and overall survival) of gynecologic carcinosarcoma, a rare, aggressive, and understudied gynecologic malignancy. This retrospective review included all patients with gynecologic cancers diagnosed and treated at a single tertiary care comprehensive cancer center between January 2012 and May 2021. A total of 2116 patients were eligible for review, of which 84 cases were identified as carcinosarcoma: 66 were uterine (5.2% of uterine cancers), 17 were ovarian (3.6% of ovarian cancers), 1 was cervical (0.28% of cervical cancers), and 1 was untyped. Of the patients, 76.2% presented advanced-stage disease (stage III/IV) at the time of diagnosis. Minority patients were more likely to present with stage III/IV (p < 0.0001). The majority of patients underwent surgical resection followed by systemic chemotherapy with carboplatin and paclitaxel. The median PFS was 7.5 months. Of the patients, 55% were alive 1 year after diagnosis, and 45% were alive at 5 years. In the studied population, minorities were more likely to present with more advanced disease. The rate of gynecologic carcinosarcomas was consistent with historical reports.

show abstract

“…33 Further development of hormone therapy is warranted as evidence suggests that, particularly in combination with other treatment regimens, it may benefit specific subgroups of patients in the firstline setting for metastatic or recurrent EC. 34 35,36 Patients should discuss their treatment options with a multidisciplinary team of healthcare providers, including gynecologic oncologists, radiation oncologists, medical oncologists and other specialists, to tailor a personalized treatment plan based on their circumstances. 25…”

Section: Hormone Therapymentioning

confidence: 99%

Endometrial Cancer: Updates in Molecular Characterization and Treatment Opportunities

2024

healthbook TIMES Onco Hema

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most prevalent gynecological malignancy and the fifth most common type of female cancer in Switzerland. With an increasing incidence worldwide, EC represents a significant health and economic burden that will continue to grow. This review article aims to provide an overview of topics such as the epidemiology of EC, its risk determinants, advancements in tumor molecular subtyping, how molecular subtyping is changing risk ratification and disease staging, as well as updates to treatment recommendations on patient therapy from international guiding bodies. In particular, the stratification of patients by molecular subtype has led to advances in disease staging and has provided physicians with greater insight into selecting therapies individualized to the patient's tumor type. We will also review the various treatment modalities available for patients with EC and briefly cover ongoing clinical research in this field, including novel monotherapies and combination therapies in both newly diagnosed and recurrent disease.

show abstract

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer

Cited by 6 publications

References 15 publications

Exploration of the Correlation Between GRHL1 Expression and Tumor Microenvironment in Endometrial Cancer and Immunotherapy

Exploration of the Correlation Between GRHL1 Expression and Tumor Microenvironment in Endometrial Cancer and Immunotherapy

Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience

Endometrial Cancer: Updates in Molecular Characterization and Treatment Opportunities

Contact Info

Product

Resources

About